NEUROCRINE BIOSCIENCES, INC.

NEUROCRINE BIOSCIENCES, INC. logo
πŸ‡ΈπŸ‡ͺSweden
Ownership
Public
Established
1992-01-01
Employees
1.4K
Market Cap
$15.4B
Website
http://www.neurocrine.com
Clinical Trials
Related News

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

Phase 2
Completed
Conditions
Tourette Syndrome
Interventions
Drug: Placebo
Drug: NBI-98854
First Posted Date
2016-02-10
Last Posted Date
2021-01-15
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
98
Registration Number
NCT02679079

Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

Phase 2
Completed
Conditions
Tourette Syndrome
Interventions
Drug: Placebo
Drug: NBI-98854
First Posted Date
2015-10-21
Last Posted Date
2020-05-07
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
124
Registration Number
NCT02581865

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

First Posted Date
2015-10-02
Last Posted Date
2021-06-14
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
110
Registration Number
NCT02566759

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

Phase 1
Completed
Conditions
Depressive Disorder
Interventions
Drug: TAK-653 Placebo
Drug: TAK-653
First Posted Date
2015-09-25
Last Posted Date
2021-03-03
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
88
Registration Number
NCT02561156
Locations
πŸ‡¬πŸ‡§

Hammersmith Medicines Research, London, United Kingdom

Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Phase 3
Completed
Conditions
Tardive Dyskinesia
Interventions
Drug: NBI-98854
First Posted Date
2015-04-01
Last Posted Date
2018-11-30
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
167
Registration Number
NCT02405091

Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

Phase 1
Withdrawn
Conditions
Congenital Adrenal Hyperplasia
Interventions
Drug: NBI-77860
First Posted Date
2015-01-29
Last Posted Date
2015-06-11
Lead Sponsor
Neurocrine Biosciences
Registration Number
NCT02349503

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Phase 3
Completed
Conditions
Tardive Dyskinesia
Interventions
Drug: NBI-98854
Drug: Placebo
First Posted Date
2014-10-24
Last Posted Date
2017-07-11
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
234
Registration Number
NCT02274558

Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome

Phase 1
Completed
Conditions
Tourette Syndrome
Interventions
Drug: NBI-98854
First Posted Date
2014-10-03
Last Posted Date
2016-01-07
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
36
Registration Number
NCT02256475

Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

Phase 1
Completed
Conditions
Parkinson's Disease
Interventions
Biological: VY-AADC01
First Posted Date
2013-10-31
Last Posted Date
2020-03-03
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
15
Registration Number
NCT01973543
Locations
πŸ‡ΊπŸ‡Έ

University of California, San Francisco, San Francisco, California, United States

πŸ‡ΊπŸ‡Έ

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

First Posted Date
2013-08-06
Last Posted Date
2014-01-16
Lead Sponsor
Neurocrine Biosciences
Target Recruit Count
24
Registration Number
NCT01916993
Locations
πŸ‡ΊπŸ‡Έ

Orlando Clinical Research Center, Orlando, Florida, United States

πŸ‡ΊπŸ‡Έ

DaVita Clinical Research, Lakewood, Colorado, United States

πŸ‡ΊπŸ‡Έ

Davita Clinical Research, Minneapolis, Minnesota, United States

Β© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy